Geriatric Nursing
Volume 28, Issue 4 , Pages 212-217 , July 2007

Are Statins Safe?

References 

  1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation. 2002;106:3143–3421
  2. Grundy SM. The issue of statin safety: where do we stand?. Circulation. 2005;111:3016–3019
  3. Grundy SM, Cleeman JI, Bairey MN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  4. Gotto AM. Statins, cardiovascular disease, and drug safety. Am J Cardiol. 2006;97(suppl):3C–5C
  5. Talbert RL. Safety issues with statin therapy. J Am Pharm Assoc. 2006;46:479–490
  6. Wilkinson GR. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In:  Hardman JG,  Limbird LE,  Gilman AG editor. Goodman and Gilman’s the pharmacological basis of therapeutics. 10th ed.. New York: McGraw Hill; 2001;p. 971–1002
  7. Rätz Bravo AE, Tchambaz L, Krähenbahl-Melcher A, et al. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf. 2005;28:263–275
  8. Einarson TR, Metge CJ, Iskedjian M, Mukherjee J. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme a reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther. 2002;24:2126–2136
  9. Bays H. Statin safety: an overview and assessment of the data—2005. Am J Cardiol. 2006;97(suppl):6C–26C
  10. Schneck DW, Birmingham BK, Zlikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004;75:455–463
  11. Lipitor (atorvastatin) Product Information. New York: Pzifer, Inc; 2004;July
  12. National Kidney Foundation. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI). Am J Transplant. 2004;4(suppl 7):13–53
  13. Clinical Pharmacology On-line. Gold Standard Inc; 2007;Available at: http:www.clinicalpharmacology.com.
  14. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006;97(suppl):27C–31C
  15. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97(suppl):77C–81C
  16. Vytorin (ezetimibe-simvastatin) Product Information. North Wales, PA: Merck/Schering-Plough Pharmaceuticals; 2005;
  17. Zetia (ezetimibe) Product Information. North Wales, PA: Merck/Schering-Plough Pharmaceuticals; 2005;
  18. McKenney JM, Davison MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(suppl):89C–94C
  19. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol. 2006;97(suppl):69C–76C
  20. Law M, Rudnicka AR. Statin safety: evidence from the published literature. Am J Cardiol. 2006;97(suppl 8):52C–60C
  21. Kasiske BL, Wanner C, O’Neill C. An assessment of statin safety by nephrologists. Am J Cardiol. 2006;97(suppl):82C–85C
  22. Ballantyne CM, Corsini A, Davison MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163:553–564

PII: S0197-4572(07)00170-X

doi: 10.1016/j.gerinurse.2007.06.005

Geriatric Nursing
Volume 28, Issue 4 , Pages 212-217 , July 2007

Article Tools

* Image Usage & Resolution